Evaluation of the Use of Granulocyte Colony Stimulating Factor (GCSF) in Post Kasai Type 3 Biliary Atresia
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY
The aim of the study is to evaluate the use of Granulocyte Colony Stimulating Factor (GCSF) on the clinical and biochemical outcome of type 3 biliary atresia post kasai.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 20 days
Maximum Age: 1
Healthy Volunteers: t
View:
• Infants with initial diagnosis of biliary atresia with biliary atresia score \> 23.927 will be allocated for Kasai porto-enterostomy with intra-operative cholangiogram reaching type 3 biliary atresia anatomy as a final diagnosis.
Locations
Other Locations
Egypt
National Liver Institute
RECRUITING
Cairo
Contact Information
Primary
Marwa Narwa Foad Asker, master
marwafoadali@gmail.com
+201008913103
Backup
Behairy Behairy El Sayed Behairy, MD
behairyelsayed@yahoo.com
+201001847754
Time Frame
Start Date: 2024-12
Estimated Completion Date: 2026-10-30
Participants
Target number of participants: 40
Treatments
No_intervention: biliary atresia without GCSF
20 infants with the final diagnosis of biliary atresia type 3 (supported by the liver histology and intra-operative finding) for GCSF after Kasai operation will not receive GCSF.
Experimental: biliary atresia with GCSF
20 infants with the final diagnosis of biliary atresia type 3 (supported by the liver histology and intra-operative finding) for GCSF after Kasai operation will receive GCSF.
Related Therapeutic Areas
Sponsors
Leads: National Liver Institute, Egypt